A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Castro, Jessica ^a   Ribó, Marc ^a   Navarro, Susanna ^b   Nogués, Maria V ^b   Vilanova, Maria ^a   Benito, Antoni ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; PROTEIN P46; PROTEIN P53; RANPIRNASE; RIBONUCLEASE; RIBONUCLEASE PE5; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CASPASE; CDKN1A PROTEIN, HUMAN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; RECOMBINANT PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYMATIC ASSAY; ENZYME INACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ESCHERICHIA COLI; GENETICS; HELA CELL; IC 50; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ESCHERICHIA COLI; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MITOGEN-ACTIVATED PROTEIN KINASE 8; RECOMBINANT PROTEINS; RIBONUCLEASES;

EID: 78651074921     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-9     Document Type: Article

References (54)

1. Rybak SM, Newton DL. Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 1999, 253(2):325-335. 10.1006/excr.1999.4718, 10585255.
2. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 1988, 21(3):169-182.
3. Ardelt W, Shogen K, Darzynkiewicz Z. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 2008, 9(3):215-225. 10.2174/138920108784567245, 2586917, 18673287.
4. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005, 23(7):643-650. 10.1080/07357900500283143, 16305992.
5. Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993, 268(14):10686-10693.
6. Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K, Darzynkiewicz Z. Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther 2008, 7(7):1104-1108. 10.4161/cbt.7.7.6172, 2577768, 18443430.
7. Vasandani VM, Wu YN, Mikulski SM, Youle RJ, Sung C. Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily. Cancer Res 1996, 56(18):4180-4186.
8. Vasandani VM, Burris JA, Sung C. Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother Pharmacol 1999, 44(2):164-169. 10.1007/s002800050962, 10412952.
9. Leland PA, Staniszewski KE, Kim BM, Raines RT. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 2001, 276(46):43095-43102. 10.1074/jbc.M106636200, 11555655.
10. Bosch M, Benito A, Ribo M, Puig T, Beaumelle B, Vilanova M. A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 2004, 43(8):2167-2177. 10.1021/bi035729+, 14979713.
11. Rodriguez M, Benito A, Tubert P, Castro J, Ribo M, Beaumelle B, Vilanova M. A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. J Mol Biol 2006, 360(3):548-557. 10.1016/j.jmb.2006.05.048, 16780873.
12. Tubert P, Rodriguez M, Ribo M, Benito A, Vilanova M. The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity. Invest New Drugs 2010,
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
14. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17):3194-3200. 10.1200/JCO.2003.02.153, 12860964.
15. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004, 4(4):333-339. 10.1016/j.coph.2004.02.006, 15251125.
16. Leland PA, Schultz LW, Kim BM, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 1998, 95(18):10407-10412. 10.1073/pnas.95.18.10407, 27907, 9724716.
17. Canals A, Ribo M, Benito A, Bosch M, Mombelli E, Vilanova M. Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability. Protein Expr Purif 1999, 17(1):169-181. 10.1006/prep.1999.1112, 10497083.
18. Ribo M, Benito A, Canals A, Nogues MV, Cuchillo CM, Vilanova M. Purification of engineered human pancreatic ribonuclease. Methods Enzymol 2001, 341:221-234. 10.1016/S0076-6879(01)41154-2, 11582779.
19. Ribo M, Bosch M, Torrent G, Benito A, Beaumelle B, Vilanova M. Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase. Eur J Biochem 2004, 271(6):1163-1171. 10.1111/j.1432-1033.2004.04020.x, 15009195.
20. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995, 4(11):2411-2423. 10.1002/pro.5560041120, 2143013, 8563639.
21. Benito A, Ribo M, Vilanova M. On the track of antitumour ribonucleases. Mol Biosyst 2005, 1(4):294-302. 10.1039/b502847g, 16880994.
22. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005, 15(1):36-42. 10.1038/sj.cr.7290262, 15686625.
23. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001, 98(24):13681-13686. 10.1073/pnas.251194298, 61101, 11717429.
24. Matlashewski G, Banks L, Pim D, Crawford L. Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem 1986, 154(3):665-672. 10.1111/j.1432-1033.1986.tb09449.x, 2419131.
25. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997, 14(4):499-506. 10.1038/sj.onc.1200855, 9053847.
26. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986, 261(33):15544-15549.
27. Gehrmann ML, Fenselau C, Hathout Y. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J Proteome Res 2004, 3(3):403-409. 10.1021/pr0340577, 15253420.
28. Shi Z, Liang YJ, Chen ZS, Wang XH, Ding Y, Chen LM, Fu LW. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol Rep 2007, 17(4):969-976.
29. Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000, 60(7):1983-1994.
30. Haigis MC, Kurten EL, Raines RT. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 2003, 31(3):1024-1032. 10.1093/nar/gkg163, 149185, 12560499.
31. Grabarek J, Ardelt B, Du L, Darzynkiewicz Z. Activation of caspases and serine proteases during apoptosis induced by onconase (Ranpirnase). Exp Cell Res 2002, 278(1):61-71. 10.1006/excr.2002.5568, 12126958.
32. Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R, von Deimling A, Doerr HW, Shogen K, Cinatl J. Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett 2007, 250(1):107-116. 10.1016/j.canlet.2006.09.018, 17084521.
33. Ardelt B, Juan G, Burfeind P, Salomon T, Wu JM, Hsieh TC, Li X, Sperry R, Pozarowski P, Shogen K, et al. Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress. Int J Oncol 2007, 31(3):663-669.
34. Jacotot E, Ferri KF, Kroemer G. Apoptosis and cell cycle: distinct checkpoints with overlapping upstream control. Pathol Biol (Paris) 2000, 48(3):271-279.
35. Ye F, Che Y, McMillen E, Gorski J, Brodman D, Saw D, Jiang B, Zhang DY. The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells. Nutr Cancer 2009, 61(4):530-537. 10.1080/01635580902803719, 19838925.
36. Takezawa K, Okamoto I, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K. Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer 2010, 103(3):354-361. 10.1038/sj.bjc.6605793, 20628382.
37. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75(4):805-816. 10.1016/0092-8674(93)90499-G, 8242751.
38. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369(6481):574-578. 10.1038/369574a0, 7911228.
39. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998, 18(1):629-643. 121530, 9418909.
40. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997, 17(8):4877-4882. 232340, 9234744.
41. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, Stancou R, Badie C, Haddada H, Chouaib S. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 1999, 18(39):5464-5472. 10.1038/sj.onc.1202919, 10498900.
42. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, Benamouzig R, Arber N. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006, 42(3):422-426. 10.1016/j.ejca.2005.11.009, 16426843.
43. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, Ishikawa T, Tahara E, Yasui W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000, 88(6):992-997. 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9, 11093826.
44. Goke R, Goke A, Goke B, El-Deiry WS, Chen Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001, 64(2):75-80. 10.1159/000048843, 11684819.
45. Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P, Staedel C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000, 161(1):17-26. 10.1016/S0304-3835(00)00586-3, 11078909.
46. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996, 381(6585):804-806. 10.1038/381804a0, 8657286.
47. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, Holbrook NJ. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000, 20(5):1713-1722. 10.1128/MCB.20.5.1713-1722.2000, 85354, 10669748.
48. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL, Chambers TC. Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem 2004, 279(12):11957-11966. 10.1074/jbc.M304935200, 14704147.
49. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M, Bilter GK, Stein B. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 2005, 313(1):325-332. 10.1124/jpet.104.078873, 15626722.
50. Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ, Magun BE. Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNAdamage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun 2000, 4(2):122-128. 10.1006/mcbr.2000.0266, 11170843.
51. Smith MR, Newton DL, Mikulski SM, Rybak SM. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp Cell Res 1999, 247(1):220-232. 10.1006/excr.1998.4317, 10047464.
52. Tsai SY, Ardelt B, Hsieh TC, Darzynkiewicz Z, Shogen K, Wu JM. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB. Int J Oncol 2004, 25(6):1745-1752.
53. Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z. The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 2008, 7(20):3258-3261. 2586937, 18927512.
54. Montanaro L, Trere D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol 2008, 173(2):301-310. 10.2353/ajpath.2008.070752, 2475768, 18583314.